Howard Fillit, MD
@a_hfillit
Followers
1K
Following
140
Media
18
Statuses
217
Co-Founder and Chief Science Officer @TheADDF. Geriatrician. Neuroscientist. Philanthropy Executive. #Alzheimers Expert. Opinions are my own.
New York, NY
Joined April 2014
RT @TheADDF: ADDF's Inaugural Scientific Summit united top scientists in #Alzheimers. Daniel Skovronsky of @EliLillyandCo received the Melv….
0
2
0
RT @TheADDF: At #CTAD24, roundtable on #combinationtherapy highlights new era of #Alzheimers, which is moving closer to a #precisionmedicin….
0
10
0
RT @markroithmayr: Brilliant panel on the Biology of Aging at #ADPD2024 lead by @niranjanbose featuring @ARUK_SusanK @a_hfillit and….
0
3
0
RT @adpdnet: Inspiring start of Day 3 at #ADPD2024 with @a_hfillit 🤩.“We need to foster collaboration between the #geroscience and #neurosc….
0
4
0
RT @TheADDF: Today #ADDF Co-Founder and Chief Science Officer @a_hfillit delivered a poignant plenary lecture at #ADPD2024 on why the biolo….
0
3
0
Great opportunity to advance biomarker research for Alzheimer's disease!.
Our friends and partners at Gates Ventures are partnering w/ @NACCData to fund up to 3 proposals (OPEN TO ANYONE) at $250k-$1M, focused on advancing #Alzheimers and related dementias research and discovery through digital innovation! Learn more to apply:
0
0
1
RT @TheADDF: The ADDF is thrilled to announce a new, one-of-a-kind partnership with FINGERS Brain Health Institute around #PrecisionPrevent….
0
11
0
RT @TheADDF: Today at #AAIC23, @EliLillyandCo announced the anti-amyloid #donanemab slows #CognitiveDecline by 35%. @a_hfillit notes this s….
0
12
0
RT @TheADDF: Today's #FDA approval of #leqembi marked a momentous day in the #Alzheimers field. @a_hfillit notes how this approval will ser….
0
28
0
Aging is the leading risk factor for #Alzheimers, so we must leverage #CombinationTherapy to target the many different pathologies based on the biology of aging & #comorbidities that lead to its onset. The truth is, no single drug will effectively treat and/or cure the disease.
Most of these changes leading to AD are aging, yet no AD therapy addresses the underlying aging process
0
4
7
Today's endorsement of Leqembi from the FDA Advisory Committee is encouraging news, but our goal is to develop multiple novel therapies based on the biology of aging to be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks.
The #FDA Advisory Committee voted that anti-amyloid #Leqembi shows clinical benefit in early #Alzheimers disease. Our CSO, @a_hfillit, discusses how the milestone underscores the need to develop the next generation of drugs based on the biology of aging:
0
2
6
I’m excited to share a new $200M gift from the Lauder family will fuel @TheADDF to advance the next generation of drugs based on the #biologyofaging, allowing us to explore the full potential of the pipeline and move the most promising research forward:
2
2
13
As we enter the, "golden age of drug discovery," as stated in @ginakolata's article, it's important to identify new #biomarkers to reduce the costs of developing drugs for diseases, like #Alzheimers, which enable us to run more rigorous & efficient trials
nytimes.com
A wave of new treatments have cured devastating diseases. When the costs are too much, even for the insured, patients hunt for other ways to pay.
0
3
8
Today marks a milestone moment for the #Alzheimers field with the approval of lecanemab, but there remains a pressing need for a new generation of drugs that target a whole host of underlying factors based on our understanding of the biology of aging.
The accelerated approval of #lecanemab is welcome news for the millions living with #Alzheimers, but we have more to do. Drugs will only be beneficial if the right ones are given to the right patient at the right time, and for that we need new #biomarkers.
0
2
5
Today's approval of #lecanemab is an encouraging step toward having the multiple drugs we will need to combine in personalized treatments and address each patient's unique #Alzheimers pathology in order to provide meaningful relief.
0
0
5
RT @TheADDF: Last week at the #MIHealthSummit, the #ADDF's @a_hfillit joined other thought leaders for a panel on @ARPA_H, sharing innovati….
0
5
0
While data from #gantenerumab is disappointing for the many patients living with #Alzheimers, the #ADDF remains optimistic about the state of Alzheimer's drug development research. Today's diverse pipeline shows 75% of drugs explore novel targets based on the biology of aging.
New data shows #Gantenerumab failed to meet its primary endpoint. While anti-amyloid therapies are a starting point, there is an urgent need to develop a new generation of drugs that target a whole host of underlying #Alzheimers causes. See ADDF statement:
0
5
13
RT @TheADDF: Clearing of #amyloid plaques resulting from drugs like #lecanemab has shown modest benefit that by itself may not make a signi….
wsj.com
Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited.
0
8
0
Amidst news on anti-#amyloid therapies, hope continues to lie in the next generation of #Alzheimers drugs that explore other targets based on the biology of aging. Many of these drugs are in development, with 75% of drugs in the pipeline now targeting non-amyloid pathways.
Anti #amyloid drugs remain one piece of the puzzle in our fight against #Alzheimers says @a_hfillit, commenting on new data showing #lecanamab slowed #cognitivedecline, but there is still a need for a new generation of drugs based on the #BiologyofAging:
0
4
12
I feel more optimism now than ever before. As I explained to @davebriggstv, aging is the leading risk factor for #Alzheimers which is why treatments informed by the #BiologyofAging are critical. ADDF support will help these treatments cross the finish line
1
0
5